Examples
Worked examples
- Is an instance
A randomized, double-blind, placebo-controlled Phase 3 trial with a single prespecified primary efficacy endpoint, sample size fixed by an a priori power calculation, and protocol design agreed with FDA in advance — submitted as one of two adequate and well-controlled trials supporting an NDA, per FDA's usual two-trials expectation under 21 CFR 314.126.
- Is an instance
A single, unusually persuasive, multicenter Phase 3 trial submitted as the sole pivotal study supporting approval, relying on FDA's narrower 'single trial' pathway described in its guidance <em>Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products</em> — permitted only where the trial result is highly statistically compelling and supported by strong corroborating evidence (e.g., a persuasive dose-response relationship or supportive mechanistic/biomarker data).
Counter-examples
Looks similar, but isn't
- Not an instance
A Phase 1 dose-escalation study establishing tolerability and pharmacokinetics is not registrational — it is exploratory, not powered on a clinical efficacy endpoint, and not intended by design to support a marketing application on its own.
- Not an instance
A Phase 2 proof-of-concept trial used only to select a dose or generate a hypothesis for a later confirmatory study is not itself registrational, even though its data may later appear in the application as supportive evidence — the trial that actually anchors the substantial-evidence claim is the one purpose-built and prespecified for that role.
- Not an instance
A post-approval Phase IV commitment trial is not registrational for the indication already approved, since the marketing application it would support has already been granted; a late-phase Phase IIIb study run in parallel with an initial NDA submission is also generally not itself the pivotal evidence, though it may become registrational for a subsequent label expansion.
Editorial commentary
A registrational trial — also called a pivotal trial — is a clinical study designed and conducted specifically to generate the primary efficacy and safety evidence submitted in a marketing application, most commonly a New Drug Application (NDA) or Biologics License Application (BLA) to FDA, or the equivalent dossier to another regulator. The defining feature is regulatory purpose and design intent, not phase number: a registrational trial is prospectively built as an adequate and well-controlled investigation under 21 CFR 314.126, with a single prespecified primary endpoint, a locked statistical analysis plan, and a sample size set by an a priori power calculation — typically agreed with the regulator in advance through a Special Protocol Assessment.
Why the distinction matters
Section 505(d) of the Federal Food, Drug, and Cosmetic Act requires ‘substantial evidence’ of effectiveness before FDA can approve a new drug, and FDA has long interpreted that historically to mean results from more than one adequate and well-controlled trial. FDA’s guidance Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products describes both the conventional two-trials expectation and the narrower circumstances — an unusually persuasive single-trial result plus strong corroborating evidence — under which one pivotal trial can be sufficient. Calling a trial ‘registrational’ signals to everyone involved (sponsors, CROs, biostatisticians, regulatory affairs staff, and research administrators managing the underlying grants or budgets) that its design cannot be altered opportunistically after the fact: the primary endpoint, population, and analysis are fixed before unblinding precisely because this is the evidence a marketing approval decision will rest on.
How it differs from exploratory and early-phase trials
Phase 1 studies (tolerability, pharmacokinetics) and most Phase 2 studies (dose-finding, early efficacy signal, hypothesis generation) are exploratory: they are not powered on a confirmatory clinical endpoint and are not designed, on their own, to satisfy the substantial-evidence standard. Their data can and does appear in a marketing application as supportive context, but they are not the trial the application’s efficacy claim is built on. See CASRAI’s clinical trial phases guide for the full Phase 1–4 sequence. A registrational trial is usually, but not always, a Phase 3 study — accelerated-approval and some rare-disease programs instead rely on a well-controlled Phase 2 trial measuring a surrogate or intermediate endpoint, with a confirmatory Phase 3 or Phase 4 trial required afterward to verify the predicted clinical benefit.
How it relates to late-phase studies
CASRAI’s dictionary separately covers the Late-Phase Clinical Study — the industry convention for Phase IIIb and Phase IV studies conducted at or after NDA/BLA submission. The two concepts are easy to conflate but describe different things: ‘registrational’ is about a trial’s evidentiary role in an approval decision, while ‘late-phase’ is about timing relative to submission. A Phase IIIb trial run in parallel with the initial pivotal submission is not itself registrational for that first approval, but a similarly timed trial can become registrational later if it is the pivotal evidence for a subsequent supplemental application or label expansion.
Operational implications for research administration
Because a registrational trial’s protocol, endpoints, and statistical plan are effectively frozen once agreed with the regulator, budget and timeline changes downstream of that agreement carry outsized risk — a protocol amendment that alters the primary endpoint after alignment with FDA can require renegotiating the regulatory pathway itself, not just an IRB or contract amendment. Research administrators supporting registrational-stage work typically see heavier data-management, monitoring, and quality-assurance requirements (including readiness for an FDA BIMO inspection) than at earlier phases, reflecting the trial’s direct evidentiary weight in an approval decision.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Registrational Trial"
vocab-term-identifier="https://casrai.org/dictionary/term/registrational-trial" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/registrational-trial",
"name": "Registrational Trial",
"identifier": "https://casrai.org/dictionary/term/registrational-trial",
"description": "A registrational trial (also called a pivotal trial) is a clinical study designed and executed specifically to generate the primary efficacy and safety evidence submitted in a marketing application — a New Drug Application (NDA), Biologics License Application (BLA), or comparable submission — to a regulatory authority such as FDA. What makes a trial ‘registrational’ is not its phase number but its regulatory purpose: it is prospectively designed as an adequate and well-controlled investigation under 21 CFR 314.126, with a prespecified primary endpoint and statistical analysis plan agreed with the regulator (often via a Special Protocol Assessment), and powered to provide the ‘substantial evidence of effectiveness’ the Federal Food, Drug, and Cosmetic Act requires for approval. Most registrational trials are Phase 3 studies, but a well-controlled Phase 2 trial can serve the same function in accelerated-approval or rare-disease programs where a full Phase 3 program is used to confirm benefit post-approval.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/registrational-trial",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-23T05:32:48",
"inLanguage": "en"
}
